Ferring Pharma, based in Switzerland, has announced the opening of a new formulation plant in Hyderabad, India, to manufacture its Pentasa product (Mesalazine).
Ferring will invest around € 60 million (roughly Rs 500 crore) in its production plant over the next 2-3 years. Pentasa is a Ferring medicine used to treat and control inflammatory bowel illnesses (IBD), such as ulcerative colitis and Crohn’s disease, over the long term. It’s given to treat the mild to moderate symptoms of active IBD, and it’s also commonly used as a maintenance medication to prevent recurring bouts.
With the exception of the United States, Pentasa is accessible as tablets and granules (sachets) across Europe and the rest of the globe.
